This study investigates how glioblastoma, an aggressive type of brain cancer, uses a hidden “lipid-remodelling” technique to continue expanding. It is difficult to identify new biological vulnerabilities to develop effective treatments for dealing with glioblastoma, which has extremely low survival rates.
A protein called CLPTM1L was highly emphasised in this study. This helps move the fats (lipids) that perform the function of creating cell membranes. It is situated inside a cell component called the endoplasmic reticulum (ER). The primary objective of research is to explain how the protein is involved in the development and maintenance of unique membrane regions that are supposed to sustain potential growth signals from a known receptor called EGFR, which acts as a key factor in glioblastoma.
Read More: A New Hope Against Brain Cancer: How Personalised DNA Vaccines Are Changing Glioblastoma Treatment
Understanding the main theme
The core concept is that cancer cells do not just change genes; they also cleverly reorganise their cell membranes to boost growth signals. Lipid rafts are nothing but tiny, densely packed rafts found in the outer layer of the cell membrane, serving as a platform by congregating crucial signal proteins to deliver a powerful ‘Glow & Divide’ signal.
The endoplasmic reticulum lipid scramblase CLPTM1L facilitates lipid interbilayer transfer to enhance the synthesis of particular complex lipids and GPI-anchored proteins. In conclusion, this study shows that CLPTM1L controls the distribution and arrangement of essential lipids for the preservation of lipid raft integrity, which stabilises the expression of the cell-surface epidermal growth factor receptor (EGFR) to promote oncogenic signalling and tumour formation.
Research Details
Under the direction of Prof. Junfeng Bi and associates at Fudan University, the research team integrated mouse models, cell studies, and data analysis. In order to determine which lipid-handling proteins are changed in tumours, they first examined cancer databases. They discovered that CLPTM1L is frequently amplified and highly expressed in many malignancies, including glioblastoma, where higher levels were associated with worse patient survival in two separate cohorts.
In the lab, they employed glioblastoma cell lines and 3D tumour spheres, lowering CLPTM1L levels (knockdown/depletion) or boosting them (overexpression) to investigate impacts on cell proliferation and signalling. Additionally, they employed an inducible CLPTM1L knockdown technique in an orthotopic glioblastoma xenograft mouse model, in which human GBM cells are implanted into the mouse brain to observe the effects of CLPTM1L blockade on tumour growth and survival in living mice.
Read More: Taming Tumour Chaos: A New Path to Better Glioblastoma Treatment
Major findings
According to the study, CLPTM1L actively promotes the proliferation of tumour cells in addition to having a correlation with cancer. Decreasing CLPTM1L in glioblastoma cell lines resulted in a notable reduction in cell viability, proliferation, and tumour sphere growth, changes that cannot be reversed by reinitiating CLPTM1L levels. In contrast, heightened levels of CLPTM1L led to enhanced colony formation and sped up the growth of non-tumour cells.
Mechanistically, the loss of CLPTM1L caused a significant decrease in raft-associated elements like phosphatidylserine, glycosphingolipids, and GPI-anchored proteins, which in turn caused a significant drop in the raft marker GM1 on the cell surface. The tumour’s primary growth pathways were weakened as a result of EGFR, which typically resides in these GM1-rich rafts, being reduced at the plasma membrane and diverted into lysosomes for destruction. Blocking this pathway disrupted the ERK pathway and the EGFR-mTORC1/2 pathways. In mouse models of brain tumours, inhibition of CLPTM1L substantially reduced tumour growth, inhibited EGFR-mTOR signalling, and increased survival.
Read More: How Collagen Tiles Are Transforming Brain Cancer Treatment
Author’s perspective
According to the researchers, CLPTM1L is a master regulator of EGFR-driven proliferative signalling in glioblastoma by acting as a crucial upstream organiser of membrane raft domains. They contend that the finding explains how cancer cells sustain the physical platforms required for ongoing oncogenic signalling by establishing a mechanistic connection between lipid modification in the ER and the structure of the plasma membrane.
Since many receptor tyrosine kinases rely on appropriate membrane organisation, and CLPTM1L is amplified or highly expressed in several cancers, blocking CLPTM1L may disrupt growth signals in tumours while possibly sparing normal cells that are less dependent on this pathway. CLPTM1L is consequently an attractive target for therapy. Therefore, by investigating the membrane structure underlying receptors like EGFR, this research expands the approach to cancer treatment rather than concentrating only on the receptors.
Conclusion
Overall, the findings show that CLPTM1L is essential for glioblastoma cells to modify lipids, form stable lipid rafts, and maintain EGFR signalling. This leads to a condition of driving towards aggressive tumour growth and poor outcomes. If lipid rafts are collapsed, leading to the degradation of EGFR. Eventually, shutting down the signalling pathways causes a slowdown of tumour development and survival increases in animal models when CLPTM1L is decreased or eliminated.
The main conclusion is that treating glioblastoma in addition to other malignancies that rely on comparable membrane-based signalling may be attainable through focusing on CLPTM1L or its regulation of lipid rafts.
References +
- News, N. (2026f, May 29). Scramblase CLPTM1L May Drive Glioblastoma—Neuroscience News. Neuroscience News.https://neurosciencenews.com/life-metabolism-clptm1l-glioblastoma-30785/
- CLPTM1L remodels lipid rafts to promote glioblastoma growth. (2026, May 29). EurekAlert! https://www.eurekalert.org/news-releases/1130155/
